It is essential to search for treatment-related alterations in adipose tissue metabolism and the potential markers of the occurrence of obesity in patients treated for ALL in the past, and to assess the relationships between weight, gender, anticancer treatment, and Apo concentrations. This evidence concerns the gene AOPEP and obesity due to melanocortin 4 receptor deficiency.